微泰醫療(02235.HK)持續葡萄糖監測系統產品獲藥監局批准註冊申請
微泰醫療(02235.HK)公布,國家藥監局昨日(4日)正式批准公司生產的創新產品「持續葡萄糖監測系統」(AiDEX G7)的註冊申請,該產品是由一次性葡萄糖探頭、葡萄糖信號發射器、葡萄糖信號接收器、血糖管理應用軟件及配套附件組成,可用於糖尿病成年患者的組織間液葡萄糖水平的連續或定期監測,並可提供並存儲實時葡萄糖值,供用戶跟蹤葡萄糖濃度變化的趨勢。
該產品的核心技術採用抗干擾電極設計和阻抗校正算法的電流/阻抗雙模監測技術、高分子葡萄糖滲透膜材料合成技術、單工序傳感器電極加工和葡萄糖氧化(酉每)固化工藝,屬國內首創,其臨床優勢為可實現最長14天的使用期限內無需指尖血校準。
取得國家藥監局的上市批准後,公司擬在中國商業化該產品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.